Using EUS elastography to predict complications from liver cirrhosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of endoscopic ultrasound elastography (EUS-E) in measuring liver and spleen stiffness as indicators of liver cirrhosis and portal hypertension. By assessing tissue stiffness, the study aims to predict the risk of complications such as gastroesophageal variceal bleeding, which is a significant cause of morbidity and mortality in cirrhotic patients. The study includes patients with radiologic features suggestive of cirrhosis and those with suspected advanced liver fibrosis. The methodology focuses on overcoming the limitations of traditional Fibroscan measurements, particularly in obese patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening
* Patients with suspected advanced liver fibrosis as detected by Fibroscan
* Patients with clinical evidence of hypersplenism
* Age \> 18 years
* Written informed consent available

Exclusion Criteria:

* Patients with features of decompensated cirrhosis, such as history of ascites, prior variceal bleeding, hepatic encephalopathy, hepatorenal syndrome
* Patients with history of hepatocellular carcinoma
* Patients with history of liver transplant or TIPS or shunting surgery
* Patients with portal and/or mesenteric vein thrombosis
* Moribund patients from terminal illnesses
* Patients with terminal malignancy
* Contraindications for endoscopy
* Unable to provide written informed consent
* Pregnancy

Where it's running

• Prince of Wales Hospital, The Chinese University of Hong Kong
  Sha Tin, New Territories, Hong Kong Recruiting

Study contacts

• Principal investigator: Raymond Tang, MD — Chinese University of Hong Kong
• Study coordinator: Thomas Lam, BS
• Email: thomaslam@cuhk.edu.hk
• Phone: 852-3505-3509

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating atorvastatin's effect on liver cancer risk in patients with advanced fibrosis

  This study is testing if taking atorvastatin can lower the risk of liver cancer in adults with advanced liver fibrosis who are at high risk for developing the disease.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT05028829

• Improving early diagnosis of liver disease using integrated diagnostics

  This study is trying to improve how quickly and accurately liver disease is diagnosed by combining different tests and information from around 750 patients who are at risk or have abnormal liver blood tests.

  Recruiting Manchester University NHS Foundation Trust · Manchester, Greater Manchester · NCT04666402

• Understanding liver damage and heart health in patients with NAFLD

  This study looks at how liver damage affects heart health in people with non-alcoholic fatty liver disease to see what factors might predict worsening liver problems.

  Recruiting University of Roma La Sapienza · Rome · NCT04036357

• Evaluating the effects of certain drugs on liver fibrosis

  This study is testing whether the medications Candesartan and Ramipril can help improve liver health in people with liver fibrosis caused by chronic hepatitis C.

  Recruiting Phase 3 Tanta University · Tanta · NCT03770936

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.